



Pfizer Canada ULC is the Canadian operation of Pfizer Inc., one of the world's leading biopharmaceutical companies. Our diversified health care portfolio includes some of the world's best known and most prescribed medicines and vaccines. Pfizer Inc. invested US\$ 8.65 billion in 2019 globally toward developing safe and effective medicines. To learn more about Pfizer Canada, visit [pfizer.ca](https://www.pfizer.ca) or you can follow us on LinkedIn, Facebook, Twitter or YouTube.

Pfizer Canada SRI est la filiale canadienne de Pfizer Inc., l'une des principales entreprises biopharmaceutiques à l'échelle mondiale. Notre gamme diversifiée de produits de soins de santé comprend des médicaments et des vaccins figurant parmi les plus connus et les plus prescrits dans le monde. En 2019, Pfizer Inc. a investi 8,65 milliards de dollars américains à l'échelle mondiale dans la mise au point de médicaments sûrs et efficaces. Pour en savoir plus sur Pfizer Canada, visitez le site [pfizer.ca](https://www.pfizer.ca) ou suivez-nous sur [LinkedIn](#), [Facebook](#), [Twitter](#) ou [Youtube](#).



Science for a better life



Let's stay in touch!

Scan here to never miss out on announcements and updates



That will benefit your practice and patients, including:

- Latest evidence in women's health
- Invitations to connect with Canadian and international healthcare providers
- Relevant information on Patient Support Programs
- Additions to our portfolio of products

Please feel free to connect with our Women's Health Medical Scientific Advisors, Alexander Mok (alexander.mok@bayer.com) and Erika Martire (erika.martire@bayer.com).

We look forward to speaking with you.

We are a life science company and a global leader in health care and nutrition. In Canada, we have over 1,300 passionate and innovative employees driving our three divisions: Pharmaceuticals, Consumer Health and Crop Science. For more information, please visit bayer.ca.

FR:

Restez à l'affût!

Numérisez ce code pour ne jamais rater les annonces et les mises à jour permettant



D'améliorer votre pratique et d'aider vos patients, notamment:

- Dernières données probantes sur la santé des femmes
- Invitations à entrer en contact avec des fournisseurs de soins de santé canadiens et internationaux
- Des renseignements pertinents au sujet des programmes de soutien aux patients
- Des ajouts à nos gammes de produits

N'hésitez pas à contacter nos conseillers scientifiques médicaux pour la santé des femmes, Alexander Mok (alexander.mok@bayer.com) et Erika Martire (erika.martire@bayer.com).

Nous avons hâte de parler avec vous.

Nous sommes une entreprise du secteur des sciences de la vie et un leader mondial dans les domaines des soins de santé et de la nutrition. Au Canada, nous comptons plus de 1 300 employés passionnés et innovateurs au sein de trois divisions: Produits pharmaceutiques, Produits grand public et Crop Science. Pour plus de détails, visitez le bayer.ca.

NEW in Vulvovaginal Atrophy

Intracrinology and Menopause

Discover **Prasterone** and its unique dual mode of action

PRASTERONE

PRODUCT MONOGRAPH
◆ **INTRAROSA™**
Prasterone vaginal ovules
Ovules, 6.5 mg prasterone, vaginal
Prescribed
Treatment of postmenopausal vulvovaginal atrophy

Endoceutics, Inc.
2795, Laurier Blvd, Suite 500,
Quebec, QC, Canada
G1V 4M7
www.endoceutics.com

Submission Control No: 196822

Date of Initial Approval:
October 30, 2019

Coming 2022

To receive the latest news click here
<http://www.lupinpharma.ca/intrarosa-signup>





Searchlight Pharma Inc., headquartered in Montreal, aspires to become a leading Canadian-based specialty healthcare company through best-in class execution of the search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products that improve life-long human health and wellness. With a core focus on women's health, urology, and specialty therapeutics, our team is committed to improving people's lives by bringing the right products to market. Our trusted brands include Nextstellis®, Divigel®, Addyi®, Estragyn Vaginal Cream®, Mona Lisa® IUDs, Bulkamid®, Rocaltrol® and Enablex® – visit our booth and www.searchlightpharma.com to learn more.

Mithra and Searchlight Pharma announced on March 8th, 2021 that Health Canada has approved Nextstellis®, the first and only combined oral contraceptive (COC) product based on the unique native estrogen estetrol (E4). E4 is the first new estrogen in a COC in the Canadian market in over half a century and is the only COC alternative to ethinyl estradiol-based COC pills in Canada.